CLSD - Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal RETINA® | Benzinga
- Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery -
- Current Clinical Evidence and Physician Experience Support SCS Injection as a Safe and Effective Method for Delivering Retinal and Choroidal Therapeutics -
ALPHARETTA, Ga., May 21, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that RETINA®, The Journal of Retinal and Vitreous Diseases, has published new guidelines that represent best practices for injection into the suprachoroidal space.
The publication, entitled, "Suprachoroidal Space Injection Technique: Expert Panel Guidance" was co-authored by 16 practicing retinal physicians led by Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, Houston, TX.
The guidance was developed based on current published evidence and clinical experience. The panel established consensus on the rationale for SCS injection, including potential benefits relative to other intraocular delivery methods, and current best practices in patient preparation, pre- and peri-injection management, SCS specific injection techniques, and post-injection management and follow-up.
"As the pioneers of suprachoroidal delivery, we are thrilled to have this established set of jointly developed guidelines featured in the prominent journal, RETINA, which we believe supports the use of our proven delivery platform," said George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer of Clearside. "On behalf of the entire Clearside team, we would like to thank this esteemed group of physicians whose time and effort generated such a thorough and well-supported SCS injection guidance publication."
Victor Chong, M.D., MBA, Chief Medical Officer of Clearside, added, "The suprachoroidal injection procedure using Clearside's proprietary SCS Microinjector® continues to gain clinical acceptance due to the adoption and increasing use of our FDA approved product, XIPERE® (triamcinolone acetonide injectable suspension), for uveitic macular edema, and through the exclusive use of our SCS Microinjector in six ongoing clinical trials in five serious retinal diseases: neovascular age-related macular degeneration (wet AMD), diabetic retinopathy, diabetic macular edema, uveitic macular edema, and choroidal ...